ReviewJournal of biomedicine & biotechnology2010
Thrombin inhibitors from different animals.
Review in Journal of biomedicine & biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- New insights into geraniol's antihemolytic, anti-inflammatory, antioxidant, and anticoagulant potentials using a combined biological and in silico screening strategy.Inflammopharmacology · 2022Article
- Bio-inspired hemocompatible surface modifications for biomedical applications.Progress in materials science · 2022Article
- Unleashing the potential of noncanonical amino acid biosynthesis to create cells with precision tyrosine sulfation.Nature communications · 2022Article
- Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage.Current research in neurobiology · 2022Review
- Exosite Binding in Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands.International journal of molecular sciences · 2021Review
- Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin.Journal of thrombosis and thrombolysis · 2021Article
- An Integrative Sialomic Analysis Reveals Molecules FromFrontiers in cellular and infection microbiology · 2021Article
- Therapeutic molecular targets of SSc-ILD.Journal of scleroderma and related disorders · 2020Article
- Prevalence of the prothrombin G20210A mutation among ischemic stroke patients.Journal of cardiovascular and thoracic research · 2020Article
- Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications.Critical care research and practice · 2018Review
- Investigation of Interactions between Thrombin and Ten Phenolic Compounds by Affinity Capillary Electrophoresis and Molecular Docking.Journal of analytical methods in chemistry · 2018Article
- Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding.The American journal of managed care · 2017Article
- The Butantan Institute: history and future perspectives.PLoS neglected tropical diseases · 2014Article
- Bioactive proteins and peptides isolated from Chinese medicines with pharmaceutical potential.Chinese medicine · 2014Review
- Kazal-type serine proteinase inhibitors in the midgut of Phlebotomus papatasi.Memorias do Instituto Oswaldo Cruz · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous and arterial thromboembolic diseases are still the most frequent causes of death and disability in high-income countries. Clinical anticoagulants are inhibitors of enzymes involved in the coagulation pathway, such as thrombin and factor X(a). Thrombin is a key enzyme of blood coagulation system, activating the platelets, converting the fibrinogen to the fibrin net, and amplifying its self-generation by the activation of factors V, VIII, and XI. Thrombin has long been a target for the development of oral anticoagulants. Furthermore, selective inhibitors of thrombin represent a new class of antithrombotic agents. For these reasons, a number of specific thrombin inhibitors are under evaluation for possible use as antithrombotic drugs. This paper summarizes old and new interests of specific thrombin inhibitors described in different animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.